Cenk Sumen
Keine laufenden Positionen mehr
Vermögen: - $ am 31.03.2024
Profil
Cenk Sumen worked as a Director at Thermo Fisher Scientific, Inc. and as a Senior Manager-Business Development at Minaris Regenerative Medicine LLC from 2014 to 2018.
He was also the Chief Scientific Officer at MaxCyte, Inc. from 2022 to 2024.
Currently, he is the Chief Technology Officer at Stemson Therapeutics, LLC.
Dr. Sumen received his undergraduate and doctorate degrees from Stanford University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
MAXCYTE, INC.
-.--% | 31.03.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Ehemalige bekannte Positionen von Cenk Sumen
| Unternehmen | Position | Ende |
|---|---|---|
| MAXCYTE, INC. | Chief Tech/Sci/R&D Officer | 23.01.2024 |
| THERMO FISHER SCIENTIFIC | Director/Board Member | 01.04.2018 |
Minaris Regenerative Medicine LLC
 Minaris Regenerative Medicine LLC Medical/Nursing ServicesHealth Services Minaris Regenerative Medicine LLC provides cell therapy services. It provides contract development and manufacturing organization (CDMO) services at current Good Manufacturing Practices (cGMP) standards, including clinical manufacturing, commercial manufacturing, and manufacturing development. The company was founded by Robert A. Preti and Andrew L. Pecora in 1997 and is headquartered in Allendale, NJ. | Corporate Officer/Principal | 01.04.2018 |
Stemson Therapeutics, LLC
 Stemson Therapeutics, LLC Miscellaneous Commercial ServicesCommercial Services Stemson Therapeutics, LLC is a pre-clinical stage cell therapy company that aims to cure hair loss by using induced pluripotent stem cells to regenerate the critical cells required to grow hair. The company is based in La Jolla, CA, and is passionate about delivering a scientifically based, clinically tested cure for hair loss to the millions of hair loss sufferers who seek help for their hair loss condition. Stemson's breakthrough innovation uses a novel cell engineering process to produce the cell types required to regenerate hair follicles. The company was founded in 2018 by Geoff Hamilton and a team of world-class scientists, advisors, and collaborators. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Cenk Sumen
| Stanford University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MAXCYTE, INC. | Health Technology |
| THERMO FISHER SCIENTIFIC | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Minaris Regenerative Medicine LLC
Minaris Regenerative Medicine LLC Medical/Nursing ServicesHealth Services Minaris Regenerative Medicine LLC provides cell therapy services. It provides contract development and manufacturing organization (CDMO) services at current Good Manufacturing Practices (cGMP) standards, including clinical manufacturing, commercial manufacturing, and manufacturing development. The company was founded by Robert A. Preti and Andrew L. Pecora in 1997 and is headquartered in Allendale, NJ. | Health Services |
Stemson Therapeutics, LLC
Stemson Therapeutics, LLC Miscellaneous Commercial ServicesCommercial Services Stemson Therapeutics, LLC is a pre-clinical stage cell therapy company that aims to cure hair loss by using induced pluripotent stem cells to regenerate the critical cells required to grow hair. The company is based in La Jolla, CA, and is passionate about delivering a scientifically based, clinically tested cure for hair loss to the millions of hair loss sufferers who seek help for their hair loss condition. Stemson's breakthrough innovation uses a novel cell engineering process to produce the cell types required to regenerate hair follicles. The company was founded in 2018 by Geoff Hamilton and a team of world-class scientists, advisors, and collaborators. | Commercial Services |
